Cornerstone Advisors Inc. lifted its position in shares of Eli Lilly And Co (NYSE:LLY) by 20.7% during the 1st quarter, HoldingsChannel reports. The fund owned 1,107 shares of the company’s stock after acquiring an additional 190 shares during the quarter. Cornerstone Advisors Inc.’s holdings in Eli Lilly And Co were worth $144,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of LLY. Oregon Public Employees Retirement Fund raised its position in shares of Eli Lilly And Co by 17,720.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after acquiring an additional 42,182,367 shares in the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly And Co during the 4th quarter valued at approximately $1,056,086,000. FMR LLC raised its position in shares of Eli Lilly And Co by 83.9% during the 4th quarter. FMR LLC now owns 13,687,081 shares of the company’s stock valued at $1,583,870,000 after acquiring an additional 6,242,865 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its position in shares of Eli Lilly And Co by 165.4% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock valued at $695,804,000 after acquiring an additional 3,747,482 shares in the last quarter. Finally, BlackRock Inc. increased its position in Eli Lilly And Co by 3.0% in the fourth quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after buying an additional 2,030,845 shares during the period. 79.42% of the stock is currently owned by institutional investors and hedge funds.
In other news, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $128.50, for a total transaction of $128,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Joshua L. Smiley purchased 426 shares of the stock in a transaction dated Wednesday, June 5th. The shares were acquired at an average cost of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the acquisition, the chief financial officer now directly owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. Insiders have sold 246,112 shares of company stock worth $31,888,255 over the last three months. Corporate insiders own 0.11% of the company’s stock.
LLY has been the topic of several analyst reports. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. initiated coverage on Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 target price on the stock. Guggenheim lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price on the stock. in a research report on Thursday, April 11th. Credit Suisse Group set a $121.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. Finally, UBS Group initiated coverage on Eli Lilly And Co in a research report on Wednesday, March 20th. They issued a “buy” rating and a $74.51 target price on the stock. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $119.99.
Shares of LLY opened at $112.21 on Wednesday. The firm has a market cap of $114.90 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 2.10 and a beta of 0.27. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a one year low of $84.64 and a one year high of $132.13.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company earned $1.31 earnings per share. Sell-side analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Friday, May 17th were issued a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.30%. The ex-dividend date was Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.
TRADEMARK VIOLATION NOTICE: This report was first posted by Zolmax and is owned by of Zolmax. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://zolmax.com/investing/cornerstone-advisors-inc-boosts-position-in-eli-lilly-and-co-nyselly/3111671.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What Does Beta Mean In Stock Selection
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.